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Abstract
Immune evasion is now recognized as a key feature of cancer progression. In animal models, the activity of cytotoxic
lymphocytes is suppressed in the tumour microenvironment by the immunosuppressive cytokine, Transforming Growth
Factor (TGF)-b. Release from TGF-b-mediated inhibition restores anti-tumour immunity, suggesting a therapeutic strategy
for human cancer. We demonstrate that human natural killer (NK) cells are inhibited in a TGF-b dependent manner following
chronic contact-dependent interactions with tumour cells in vitro. In vivo, NK cell inhibition was localised to the human
tumour microenvironment and primary ovarian tumours conferred TGF-b dependent inhibition upon autologous NK cells ex
vivo. TGF-b antagonized the interleukin (IL)-15 induced proliferation and gene expression associated with NK cell activation,
inhibiting the expression of both NK cell activation receptor molecules and components of the cytotoxic apparatus.
Interleukin-15 also promotes NK cell survival and IL-15 excluded the pro-apoptotic transcription factor FOXO3 from the
nucleus. However, this IL-15 mediated pathway was unaffected by TGF-b treatment, allowing NK cell survival. This
suggested that NK cells in the tumour microenvironment might have their activity restored by TGF-b blockade and both
anti-TGF-b antibodies and a small molecule inhibitor of TGF-b signalling restored the effector function of NK cells inhibited
by autologous tumour cells. Thus, TGF-b blunts NK cell activation within the human tumour microenvironment but this
evasion mechanism can be therapeutically targeted, boosting anti-tumour immunity.
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Introduction
Human tumour cells can be recognized and eliminated by the
immune system but this selective pressure favours the outgrowth of
tumours that have successfully evaded immunity [1]. Indeed, the
ability to evade the immune response is now recognized as a
hallmark of cancer [2]. Numerous mechanisms of tumour immune
evasion have been described [1,2,3,4]. In the case of cytotoxic
lymphocytes, loss of MHC class I expression by the tumour
prevents cytotoxic T lymphocyte (CTL) recognition. However, loss
of MHC class I expression favours natural killer (NK) cell
activation. Activated NK cells exocytose their cytotoxic granules
leading to the release of pro-apoptotic components (granzymes
and perforin) that kill the tumour. In addition, secretion of
interferon (IFN)-c promotes adaptive cellular immunity [5]. Like
CTL, NK cells play an important role in tumour immune
surveillance but, not surprisingly, their powerful effector functions
are countered by evasion strategies that contribute to tumour
escape [5,6,7,8]. Human NK cells express several activation
receptors important in tumour cell recognition including NKG2D,
DNAM-1 and the natural cytotoxicity receptors NKp30, NKp44
and NKp46 and several studies have identified the reduced
expression of these molecules and weakened NK cell activity in
human cancer [5,6,9,10,11,12,13].
The immunosuppressive cytokine Transforming Growth Factor
(TGF)-b plays a key role in tumour immune evasion [14]. In the
healthy immune system, TGF-b serves to blunt immune responses,
minimising self-reactivity [14,15]. Tumours exploit this activity,
and many other functions of TGF-b, to promote their progression
[14,16]. The levels of TGF-b are often elevated in the serum of
cancer patients and this is associated with systemic inhibition of
immune function, including weakened NK cell responses, and is
associated with a poor prognosis [16,17,18]. However, such
systemic effects are likely to be limited to patients with a large
tumour burden. In contrast, localised immune evasion is likely to
operate throughout tumour progression.
There is increasing evidence that the tumour microenvironment
plays a key role in regulating tumour growth, angiogenesis and
immune surveillance [3,14]. Tumour antigen-specific CTL and
NK cells demonstrate effective anti-tumour activity in vitro and
infiltrate solid tumours in vivo, yet their activity is weakened within
the tumour microenvironment [13,14,19]. Evidence from animal
studies indicates that antagonism of TGF-b activity can restore
productive tumour immunity, suggesting a therapeutic strategy
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e22842[14,20]. However, the human tumour microenvironment is much
less accessible than the peripheral circulation and does not easily
lend itself to mechanistic studies or assessment of therapeutic
strategies. We have studied human NK cell evasion using model
systems and by analysis of the malignant ascites of human ovarian
cancer. In this disease, tumour-associated NK cells and tumour
cells are relatively easy to access, enabling in vivo and ex vivo analysis
of immune evasion to be performed. Our results indicate a pivotal
role for TGF-b in the tumour localised evasion of human NK cells
and demonstrate that the suppressive effects of this cytokine on
NK cell effector function can be reversed using TGF-b antagonists
in wholly autologous, patient-derived systems ex vivo.
Results
Modelling chronic interactions between human NK cells
and tumours
In vivo, the interactions between NK cells and tumours are
chronic in nature and tumours proliferate and progress in the
continual presence of immune effector cells. We modelled this in
vitro by establishing longer-term co-cultures (one to seven days)
between tumour cell lines and interleukin (IL)-15 stimulated NK
cells from the peripheral blood of healthy donors. The NK cells
from these co-cultures exhibited reduced cell surface expression of
the activation receptors NKp30, NKG2D and DNAM-1, whereas
expression of NKp46 was largely unaffected (Figure S1). The
alterations in NK cell surface phenotype were accompanied by
decreased IFN-c production and reduced cytotoxic granule
exocytosis following restimulation of the NK cells with tumour
targets (Figure S1). However, IFN-c production after stimulation
with PMA and ionomycin was unaffected by prior co-culture,
suggesting that the inhibition of effector function was most likely
due to reduced expression of activating receptors rather than
inhibition of downstream signalling pathways (Figure S1). The
inhibition of NK cells by tumours was reversible, required NK-
tumour cell contact and was exerted by several tumour cell types.
Furthermore, a comparison of malignant versus immortalised
keratinocytes revealed greater inhibition by the cancer cells,
suggestive of a tumour immune evasion mechanism (Figure S1).
Chronic inhibition of NK cells is mediated by TGF-b
The pattern of inhibition of NK cell surface receptor expression
mediated by tumour cells closely resembled that observed when IL-
15 stimulated NK cells were treated with the immunosuppressive
cytokine TGF-b [21,22,23]. Inclusion of an anti-TGF-b antibody
into the co-culture between IL-15 stimulated NK cells and tumour
cells revealed that TGF-b blockade restored NK cell effector
function (Figure 1A, B and Figure S2) and that this was associated
with a restoration of NKp30 expression at the cell surface and
increases in both DNAM-1 and NKG2D molecules (Figure 1C).
Thus, chronic interactions between tumour and NK cells resulted in
the TGF-b dependent inhibition of NK cell effector function via the
reduced expression of NK cell activation receptors.
TGF-b antagonises IL-15 induced expression of genes
encoding NK cell activation receptors and components
of the cytotoxic apparatus
We then analysed the mechanisms by which TGF-b inhibits
NK cell function. TGF-b exerts its effects largely via the SMAD
Figure 1. TGF-b dependent inhibition of NK cells following chronic interaction with tumour cells. (A and B) NK cell effector function was
analysed following 48 hr interaction with the colorectal cancer cell line HCT116. NK cells were cultured in the presence of IL-15, either with or without
HCT116 cells, and in the presence of an anti-TGF-b antibody (or a control antibody) as indicated. Granule exocytosis (A) and IFN-c production (B) were
then analysed following restimulation with K562. The percentage of responding cells for each treatment is indicated. Both assays are one of two
independent experiments. Killing of K562 cells was also inhibited in a TGF-b dependent manner (Figure S2). (C) NK cell activation receptor expression
(as indicated) was assayed after co-culture with HCT116 in the presence of anti-TGF-b antibody (blue histogram), a control antibody (green
histogram) or by NK cells cultured in the absence of tumour cells (red histogram). Isotype control stains are shown in grey and black.
doi:10.1371/journal.pone.0022842.g001
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[22,24,25]; TGF-b treatment of IL-15 stimulated NK cells for
48 hours mimicked the results of the tumour cell-NK cell co-
cultures by reducing the cell surface expression of NKp30,
NKG2D and DNAM-1, but not NKp46 (Figure 2A). These
changes were mirrored by reduced expression of the NCR3 and
CD226 genes (encoding NKp30 and DNAM-1 respectively) but
with little change in NCR1 gene expression (encoding NKp46).
Expression of the KLRK1 gene (encoding NKG2D) was unaltered.
However, cell surface expression of NKG2D requires association
with its signalling chain, DAP10 [26], and expression of the HCST
gene (encoding DAP10) was reduced in the presence of TGF-b.I n
contrast, TGF-b did not alter expression of the CD247 gene
(Figure 2B); this encodes CD3f, the signalling chain associated
with NKp30 and NKp46. Comparing receptor expression (at the
mRNA and protein level) in unstimulated NK cells with that in IL-
15 stimulated, or IL-15 plus TGF-b treated NK cells, revealed that
TGF-b exerted these inhibitory effects by antagonising IL-15
induced gene expression.
Inhibition was not confined to alterations in NK cell surface
receptors. As with mouse CD8
+ T cells [24], TGF-b inhibited
expression of multiple components of the NK cell cytotoxic
apparatus at the mRNA and protein level. The fifteen-fold
induction of GZMB gene expression resulting from IL-15 stimula-
tion was antagonized by TGF-b treatment, whereas expression of
the adjacent GZMH gene was much less responsive to these
cytokines. These effects were manifested at the protein level
(Figure 3A). Furthermore, expression of the perforin gene (PRF1)
and CTSC (encoding the granzyme activating enzyme cathepsin C)
were induced by IL-15 and antagonized by TGF-b (Figure 3B). The
reduced expression of CTSC and GZMB was associated with
reduced proteolytic activity associated with these molecules
(Figure 3C). The cumulative effect of inhibiting NK cell activation
receptor expression and components of the cytotoxic apparatus was
reduced NK cell mediated killing of tumour target cells (Figure 3D).
Thus, TGF-b treatment inhibited the IL-15 induced expression of
key activating receptors and cytotoxic components involved in the
detection and destruction of tumour cells.
TGF-b allows IL-15 mediated NK cell survival
IL-15 also regulates NK cell survival [27,28,29]. The ability of
TGF-b to inhibit IL-15 mediated events suggested that this
survival might be impaired in the presence of TGF-b, as has been
observed for cytotoxic T cells [30]. Human NK cell survival in vitro
was enhanced by exogenous IL-15 but, unlike NK cell activation
and proliferation, survival was not subject to inhibition by TGF-b
(Figure 4A and B). TGF-b induced SMAD3 phosphorylation but
did not substantially reduce IL-15 receptor proximal signalling
events, as shown by its inability to suppress STAT5 phosphory-
lation (Figure 4C). In mouse NK cells, IL-15 mediated survival has
been linked to the inhibition of FOXO3-dependent gene
expression [29]. The phosphorylation of FOXO3 (via the PI3K/
AKT pathway) causes its retention in the cytoplasm where it is
unable to induce expression of pro-apoptotic genes [31,32].
Human NK cells cultured in the absence of exogenous cytokines
showed increased accumulation of FOXO3 in the nucleus.
Stimulation with IL-15 redistributed FOXO3 from the nucleus
to the cytoplasm, facilitating NK cell survival; this IL-15 induced
redistribution of FOXO3 was unaffected by TGF-b treatment
(Figure 4D).
Figure 2. TGF-b antagonises IL-15 induced gene expression of NK cell activation receptors. (A) Cell surface expression of NK cell
activation receptors (as indicated) by unstimulated NK cells (green histogram), IL-15 stimulated NK cells (red histogram) or NK cells treated with IL-15
and TGF-b (blue histogram). Cells were cultured for 48 hrs. Isotype control stains are shown in purple. (B) Receptor gene expression in cultures of
unstimulated NK cells (U), IL-15 stimulated cells (15) and IL-15 plus TGF-b treated NK cells (15+b). Steady-state mRNA levels were determined by
quantitative (q)RT-PCR and the results expressed as arbitrary units (with expression in unstimulated NK cells defined as 1 unit; note the different
scales). The colours correspond to the flow cytometry plots shown in (A).
doi:10.1371/journal.pone.0022842.g002
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tumour microenvironment and its reversal by TGF-b
blockade
Thus, despite antagonizing NK cell activation by IL-15, TGF-b
does not counteract IL-15 mediated survival signals. This
suggested that inhibited NK cells present in the tumour
microenvironment might have their effector function restored if
TGF-b activity could be interrupted. Obtaining human tumour-
associated NK cells is challenging and functional studies of
infiltrating NK cells are severely limited by the cell numbers
available. However, the malignant ascites associated with ovarian
cancer is a physiological niche from which tumour associated NK
cells and autologous tumour cells can be relatively easily prepared
and such tumour-associated NK cells are subject to localised
inhibition [11]. We compared the cell surface phenotype of ascites-
derived NK cells with that of matched NK cells from the patients’
peripheral blood. As found previously [11], the cell surface
expression of DNAM-1 was reduced on the tumour associated NK
cells in all cases, whereas other activation receptors were variably
affected (Figure 5A and Figure S3). In most cases, NK cells from
the patients’ peripheral blood were indistinguishable from those
isolated from healthy donors, demonstrating localised inhibition in
vivo and suggesting that NK cells entering the peritoneal tumour
microenvironment (e.g. from the blood) become inhibited
(Figure 5A and Figure S3). In agreement with this, it was possible
to confer a tumour associated-like phenotype on the patient
derived peripheral blood NK cells by co-culturing them with
autologous tumour cells. This resulted in reduced cell surface
expression of DNAM-1, NKG2D and NKp30 (Figure 5B and C),
similar to the inhibition seen with tumour cell lines. These changes
in receptor expression were dependent upon TGF-b, since an anti-
TGF-b antibody partially restored expression of these molecules at
the cell surface and boosted NK cell function accordingly
(Figure 5B, D). Moreover, SB-431542, a small molecule inhibitor
of the TGF-b signalling pathway [33], was capable of minimising
the inhibition of autologous NK cells by tumour cells (Figure 5C,
E). This inhibitor also partially restored the cell surface expression
of activation receptors but, more remarkably, it enhanced IFN-c
synthesis to the levels produced by NK cells cultured in the
absence of autologous tumour (Figure 5C and E). These effects
were also observed when SB-431542 was used in co-cultures
between NK cells and the colorectal cell line HCT116 (Figure S4).
These results demonstrated that NK cell effector function could be
efficiently restored, despite chronic interaction with autologous
tumour cells.
Discussion
These results establish a key role for TGF-b in the localised
inhibition of human tumour-associated NK cells and reveal that
this evasion pathway can be reversed by TGF-b antagonism.
Knowledge of the role of TGF-b in tumour immune evasion
comes largely from studies using animal models where disruption
of TGF-b signalling, either by genetic means or using inhibitory
agents, can restore anti-tumour immunity, identifying this evasion
pathway as a promising therapeutic target [14,20,34]. In humans,
Figure 3. TGF-b inhibits expression of components of the NK
cell cytotoxic apparatus. (A) Expression of granzymes B and H at the
protein and mRNA level. For granzyme B, NK cells were stimulated
20 ng/ml IL-15 for 48 hrs and increasing amounts of TGF-b (ranging
from 0 to 5 ng/ml). The immunoblot shows granzyme B expression
(GZMB) and actin as a loading control. For granzyme H, expression was
determined in unstimulated NK cells, NK cells treated with IL-15 and IL-
15 plus TGF-b (for 48 hrs). The blots show granzyme H (GZMH) and
actin levels. For gene expression, GZMB and GZMH steady state mRNA
levels were quantitated from unstimulated (U), IL-15 stimulated (15) and
IL-15 plus TGF-b (15+b) treated NK cells (using qRT-PCR) and expressed
as arbitrary units, with expression in unstimulated NK cells defined as 1
unit (note the different scales). (B) Expression of the cathepsin C (CTSC)
and perforin (PRF1) gene in unstimulated (U), IL-15 stimulated (15) and
IL-15 plus TGF-b (15+b) treated NK cells, determined as in (A). (C)
Protease activity in cytokine treated NK cells. Aspartase (Aspase) activity
(a measure of granzyme B activity) assayed by hydrolysis of AcIEPD-pNA
(left panel) and cathepsin C activity assayed by hydrolysis of GF-pNA
(right panel). Activity was measured in lysates derived from unstimu-
lated NK cells (U), NK cells stimulated for 48 hrs with 20 ng/ml IL-15 (15)
or IL-15 plus 5 ng/ml TGF-b (15+b). Each reaction contained lysate from
6610
5 cells and was performed in triplicate, with the mean and SD
calculated. Activity is expressed as arbitrary units. (D) NK cells were
stimulated with either 20 ng/ml IL-15 (15) or IL-15 plus 5 ng/ml TGF-b
(15+b) for 48 hrs and used in standard killing assays against K562,
OVCA433 and SKOV3 tumour cell lines at an E:T ratio of 3:1 (with
standard deviation shown).
doi:10.1371/journal.pone.0022842.g003
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cancer types and this has been linked with reduced NK cell activity
and, in particular, with reduced expression of NKG2D on NK
cells [16,18,35].
We have shown that chronic interactions occurring between
human tumours and NK cells results in localised TGF-b mediated
NK cell inhibition. Tumours fully exploit the activity of TGF-b;
they produce it in large amounts, promoting angiogenesis and
immunosuppression in the tumour microenvironment. The
tumours themselves become refractory to the potent anti-
proliferative activity of TGF-b via genetic instability and loss of
responsiveness. Thus, whilst TGF-b suppresses the malignant
phenotype in its early stages (e.g. via the inhibition of proliferation)
it ultimately fosters an environment favoring tumour progression
[14,34]. In immune evasion, TGF-b exerts suppressive effects
directly on effector cells (including cytotoxic cells) and indirectly
by promoting the differentiation of regulatory T cells, which
themselves inhibit cytotoxic cells [14,36].
Inhibition of cytotoxic cells by TGF-b occurs via SMAD-
dependent pathways and this targets the cytotoxic apparatus of
both T cells and NK cells [22,24]. In addition, SMAD3-dependent
pathways suppress NK cell activation receptor expression [22].
TGF-b mediated inhibition of expression of DNAM-1, NKG2D
and NKp30 was seen in all of the NK cell-tumour co-cultures
performed. These receptors have an established role in tumour-
mediated NK cell activation and their inhibition by TGF-b was
associated with reduced granule exocytosis, tumour killing and
IFN-c release; effector pathways that are essential for robust anti-
tumour immunity [1,37,38]. Bypassing activating receptors by
stimulating the tumour-inhibited NK cells with PMA/ionomycin
Figure 4. TGF-b does not inhibit IL-15 mediated NK cell survival. (A) NK cell proliferation in vitro. NK cells were labeled with CFSE and cultured
for five days in IL-15 alone (top panel) or IL-15 plus TGF-b (bottom panel). Cell division (as assessed by reduction in CFSE staining) was determined by
flow cytometry. The percentage of cells judged to have undergone at least one cell division is shown. (B) NK cell survival in the presence or absence
of IL-15. NK cells were cultured for five days in the absence of exogenous cytokines (unstimulated) or in the presence of IL-15 or IL-15 plus TGF-b. Cell
survival was assessed by staining with annexin V and 7-AAD. Healthy cells (lower left quadrant) are boxed and the percentage of cells within this box
are shown. (C) Signalling pathways in NK cells. Immunoblots show the phosphorylation of STAT5 (P-STAT5) and SMAD3 (P-SMAD3) in unstimulated
NK cells, IL-15 stimulated or IL-15 plus TGF-b treated. Total STAT5 and SMAD3 levels are shown as loading controls. (D) Intracellular localisation of the
FOXO3 transcription factor in unstimulated NK cells, NK cells stimulated with IL-15 or NK cells treated with IL-15 plus TGF-b (48 hrs) analysed by
confocal microscopy. The panels show FOXO3 (in green) and the nucleus (blue) with a scale bar of 5 mm. Also shown is staining in which the anti-
FOXO3 antibody was omitted and cells were stained with a secondary antibody only (2
e only).
doi:10.1371/journal.pone.0022842.g004
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suggesting that reduced cell surface expression of these receptors is
key to human tumour immune evasion. In this regard, mice
lacking these receptors are deficient in tumour immunity
[39,40,41]. Indeed, these molecules are the targets of evasion
strategies exerted by both tumours and viruses (such as Human
Cytomegalovirus), indicating their central importance to NK cell
function in vivo [42]. In ovarian cancer, DNAM-1 expression is also
reduced on tumour associated NK cells as a result of receptor-
ligand interactions [11]. Our results showed that chronic
interactions between tumour cells and NK cells in vitro lead to
the reduced expression of NKp30, NKG2D and DNAM-1,
whereas only DNAM-1 was consistently affected in vivo. This
difference is likely to reflect the multitude of evasion pathways that
operate in vivo [6,36,43,44,45]. Interestingly, the TGF-b mediated
inhibition observed here during chronic interactions required
direct contact of NK cells and tumour cells, similar to that
observed for NK cell inhibition mediated by myeloid suppressor
cells [45].
Inhibition of the cytotoxic apparatus identifies a common
mechanism by which TGF-b acts on NK cells and cytotoxic T
cells. However, TGF-b appears to differentially regulate the
survival of these cell types. TGF-b promotes the apoptosis of CD8
+
T cells during the clonal expansions and contractions that occur
during and after infection [30]. In contrast, our results show that
whilst TGF-b inhibited IL-15 mediated proliferation and activa-
tion of NK cells, it did not inhibit IL-15 mediated NK cell survival.
Both SMAD3 and STAT5 signalling pathways were active in cells
treated with IL-15 plus TGF-b and the IL-15 dependent exclusion
of FOXO3 from the nucleus was also unaffected by TGF-b
Figure 5. Human NK cell inhibition in vivo and restoration of effector function by TGF-b antagonists. (A) DNAM-1 expression on ovarian
cancer patient-derived peripheral blood NK cells (blue histograms), NK cells from the patient’s ascites (green histograms) and NK cells from peripheral
blood of a healthy donor (red histograms). Samples were analysed without stimulation from five patients (P1-5). NKp30, NKG2D and NKp46
expression from these five patients is shown in Figure S3. (B and C) Restoration of NK cell activation receptor expression after TGF-b antagonism in NK
cell-tumour co-cultures using either an anti-TGF-b antibody in (B) or SB-431542, a small molecule inhibitor of TGF-b family receptors in (C). Primary
ovarian tumour cells (from ascites fluid) were co-cultured for 48 hrs with matched peripheral blood-derived NK cells (in the presence of IL-15). The
tumour cell phenotype is shown in Figure S3B. Expression of NKp30, NKG2D and DNAM-1 was analysed on NK cells cultured in the absence of
matched tumour (red histograms), in the presence of TGF-b antagonists (blue histograms) or control agents (green histograms). Antagonists were the
anti-TGF-b antibody in (B) or SB-431542 (C), and control agents were a control antibody in (B) or DMSO, the solvent for SB-431542, in (C). Grey filled
and black histograms are isotype controls. Experiments shown in panel (B) and (C) were performed using samples from different patients. (D) and (E)
Restoration of NK cell effector function by TGF-b antagonism. Patient-derived tumour cells were co-cultured with autologous NK cells (from patient
peripheral blood) and IL-15 for two days in the presence of TGF-b antagonist, or control agent, as indicated. Effector function was assessed by IFN-c
production after restimulation with K562. SB-431542 also restored effector function to NK cells co-cultured with HCT116 (Figure S4). Experiments
shown in (D) and (E) were performed using samples from different patients.
doi:10.1371/journal.pone.0022842.g005
Tumour-Mediated Inhibition of Human NK Cells
PLoS ONE | www.plosone.org 6 September 2011 | Volume 6 | Issue 9 | e22842treatment. In addition, both IL-15 and TGF-b signalling are
coupled to AKT, the kinase responsible for FOXO3 phosphor-
ylation [29,46]. The mechanistic basis for the differential survival
responses of cytotoxic T cells and NK cells remains unclear.
However, it is likely to reflect fundamental requirements for the
homeostatic control of NK and T cell responses to infection.
Apoptosis of clonally expanding and contracting T cells is
desirable to limit self-reactivity and to provide immunological
space for repertoires of naı ¨ve cells. In contrast, NK cells are not
antigen-specific and, whilst limited clonal expansions of NK cells
do occur, there is not such a pressing need to eliminate expanded
cells post-infection. Thus, in infection TGF-b blunts the effector
function of activated NK cells but they presumably recover from
this localised inhibition allowing them to respond to subsequent
immunological challenge.
Although TGF-b may promote the apoptosis of tumour antigen-
specific CD8
+ T cells in the tumour microenvironment [30], our
data shows that the NK cells remain viable, albeit in a relatively
inactive state. Blocking TGF-b action may therefore allow recovery
of NK cell effector function and anti-tumour immunity. We were
able to reduce TGF-b mediated inhibition using an anti-TGF-b
antibody andwitha small molecule inhibitor(SB-431542)of TGF-b
receptor signalling. Most importantly, these agents restored effector
function to NK cells engaged in chronic interactions with
autologous primary ovarian cancer cells, suggesting that TGF-b
mediated immune evasion might be successfully blocked in vivo. Use
of the anti-TGF-b antibody identifies the importance of TGF-b
molecules themselves in the tumour-mediated evasion of NK cells.
However, the SB-431542 molecule inhibits Activin Like Kinases
(ALK)-4, -5 and -6 (33); these are components of several TGF-b
family receptors and it is possible that this inhibitor is releasing NK
cells from inhibition by other TGF-b family molecules in these
assays; one such candidate is activin, which is known to inhibit NK
cell production of IFN-c [47].
A number of TGF-b antagonists are being evaluated as anti-
cancer agents in clinical trials [14]. We have focused this study on
the localised inhibition of human NK cells by tumour cells.
However, within the tumour microenvironment the action of
TGF-b is manifold and inhibition of TGF-b action could
conceivably favor productive anti-tumour immunity via multiple
pathways [14]. Whilst autoimmunity is a potentially damaging side
effect of such treatment, successful elimination of tumours by the
immune system does, by definition, require a degree of self-
reactivity. The localised TGF-b mediated inhibition demonstrated
here suggests that local delivery of TGF-b antagonists may help to
reduce unwanted side effects arising from systemic blockade;
ovarian cancer may respond to the local delivery of TGF-b
antagonists used in conjunction with other immunotherapeutic
agents, such as humanized antibodies against tumour cell surface
molecules or cancer vaccines [48,49]. Our results, together with
the compelling evidence from animal models, argue that TGF-b
antagonists offer great therapeutic potential for restoring anti-
tumour immunity and suggest that the effects of these agents on
the human immune system warrants careful evaluation.
Materials and Methods
Ethics statement
Patients with advanced ovarian cancer were undergoing
paracentesis procedures as part of routine treatment for disease
at the St. James’s Institute of Oncology, Leeds UK. Peripheral
blood samples were also taken from some patients. All patients
gave informed, written consent. Approval for this study was
provided by the Leeds Teaching Hospitals NHS Trust Research
Ethics Committee.
Cell lines, antibodies and flow cytometry
Human cell lines HCT116 (colon), HaCaT (immortalised
keratinocyte) and Hela (cervical cancer) were cultured in DMEM
with 10% FCS. The ovarian cancer cell lines OVCA433 and
SKOV3 and the erythroleukaemic line K562 were cultured in
RPMI supplemented with 10% FCS. Antibodies were purchased
with the following fluorochromes; Allocophycyanin (APC),
Fluorescein isothiocyanate (FITC) and phycoerythrin (PE). The
following antibodies were used for flow cytometry (with fluoro-
chromes and clone listed); CD56 (APC; clone NCAM 6.2), CD3
(FITC; clone HIT3a), NKp30 (PE; clone p30-15), NKG2D (PE;
clone 1D11), DNAM-1 (PE; clone DX11), NKp46 (APC; clone
9E2), IFN-c (PE; clone 4S.B3) CD107a (FITC; clone H4A3),
MUC1 (FITC; clone HPMV), HER2 (FITC; clone Neu 24.7),
CD138 (PE; clone mi15) all from Becton Dickinson (Oxford, UK).
NKp46 (PE; clone 9E2) was from Miltenyi Biotec, MUC16 (PE;
675) was from Gene Tex Inc. and TGF-b (PE; 1D11) was from
R&D systems. Data was collected using an FACS Calibur or
LSRII flow cytometer (BD Biosciences) and analysed using FACS
Diva or Cellquest Pro (both from BD Biosciences) or Flowjo
software (Treestar).
Isolation and culture of human NK cells from blood and
ascites
For peripheral blood, 20–30 ml blood samples were used to
purify NK cells using a negative selection NK cell isolation kit
(Miltenyi Biotec). Purified NK cells were subsequently cultured in
DMEM, 10% human AB serum (Seralabs), 5% fetal calf serum
(FCS, Gibco) at a density of 10
6 cells/ml with no additions or
20 ng/ml recombinant human IL-15 and/or TGF-b 5 ng/ml
(both from R&D systems), or as indicated. For ascites fluid samples
(250–500 ml), cells were pelleted by centrifugation (400 g,
10 mins), washed in PBS, resuspended in RPMI supplemented
with 10% FCS and plated for 24–48 hrs. The adherent cell
fraction is heavily enriched for tumour cells. The non-adherent
fraction (removed by washing) containing the NK cells was then
applied to a Ficoll gradient (as used in the preparation of
peripheral blood mononuclear cells) and, after centrifugation, the
mononuclear fraction of cells was isolated and stained for
expression of NK cell markers.
Tumour-NK Co-cultures
NK cells were co-cultured in 6-well flat bottom plates with
tumour cell lines or ovarian tumour cells at an NK:tumour cell
ratio of 1:3. This is opposite to the typical 3:1 ratio used in killing
assays and helps to minimize killing during the co-culture and
mimic the situation in vivo where tumour cells heavily outnumber
NK cells. Each well contained 0.5-1610
6 cells and was cultured
(for 48 hrs or as otherwise indicated) in the presence of 20 ng/ml
IL-15+/210 mM SB-431542 (Tocris Bioscience) or 10 mg/ml
anti-TGF-b antibody (clone 1D11) or IgG1 isotype control
antibody. At the end of the co-culture period, cells were stained




+ phenotype. For degranulation and
IFN-c assays, NK cells were removed from the co-culture by
gentle washing (the NK cells are weakly adherent). For
degranulation, cells were then restimulated with K562 for 4 hrs,
in the presence of anti-CD107a antibody and GolgiSTOP (from
BD Biosciences). Cells were then harvested, stained with anti-
NKp46 antibody and washed before data collection. For the IFN-
Tumour-Mediated Inhibition of Human NK Cells
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e22842c production assay, NK cells were treated as for the CD107a assay
and were then fixed and permeabilised using Leucoperm reagents
(AB Serotec) and subsequently stained for intracellular IFN-c.
For killing assays after co-culture, NK cells were purified from
the co-culture using a MoFlo cell sorter (Dako Cytomation). Co-
cultured cells were stained with anti-CD138 antibody and 7-
aminoactinomycin D (7-AAD), the CD138
neg 7-AAD
neg popula-
tion consisted of .95% CD56
+CD3
neg NK cells. Sorted cells were
used in a standard 5 hr killing assay with Cell Tracker Green
(Invitrogen) labeled targets. Dead or dying target cells were
identified after propidium iodide staining [50].
NK cell proliferation and survival
Human NK cells were purified as above and loaded with 10 mM
Carboxyfluorescein succinimidyl ester-SE (CFDA-SE; Invitrogen)
for 10 mins at 37uC. Subsequently, 1 ml of FCS was added and
the cells were pelleted (300 g, 10 minutes at room temperature)
and washed twice with media. CSFE-labeled cells were cultured
with IL-15+/2 TGF-b as above. At day 5 cells were assessed for
proliferation by excitation at 488 nm using an LSRII Flow
cytometer (BD Biosciences). Data was analysed using FlowJo
software (Treestar). For survival assays, purified NK cells were
cultured in NK media with no additions or supplemented with IL-
15 or IL-15 plus TGF-b for 5 days. Cells were stained with 7-AAD
and APC conjugated annexin V in 16staining buffer (all from BD
Biosciences) to reveal cell surface phosphatidylserine and healthy
cells identified as the 7-AAD
negAnnexin V
neg.
FOXO3 localization by confocal microscopy
Indirect immunofluorescence of primary NK cells was per-
formed on unstimulated and stimulated NK cells with IL-15+/
2TGF-b (for 48 hrs), as above. Cells were allowed to adhere to
coverslips coated in poly-L-lysine (Sigma-Aldrich), fixed with 4%
paraformaldehyde for 20 mins and permeabilized using 0.5%
saponin (Sigma-Aldrich) for 10 mins before blocking in PBS
containing 1% BSA (Sigma-Aldrich). Coverslips were incubated
with rabbit polyclonal antibody against FOXO3a (Cell Signaling
Technology) for 1 hr, at room temperature and washed three
times in PBS followed, by an AlexaFluor488-conjugated goat anti-
rabbit secondary antibody (from Molecular Probes) for 1 hr at
room temperature. Following three PBS washes, coverslips were
mounted onto slides using ProLong Gold with DAPI to reveal the
nucleus (from Molecular Probes). Images were acquired with a
Nikon Eclipse C1 inverted scanning confocal microscope equipped
with an attached Hamamatsu digital camera and a 6100 Plan
Apochromat 1.4 NA oil objective (Nikon Instruments). Figures
were assembled and annotated using Adobe Photoshop 4.
Expression analysis; mRNA, protein and enzymatic assays
Steady state mRNA levels were determined by quantitative
reverse transcriptase (RT)-PCR in NK cell cultures (48 hrs, with
indicated cytokines) using Taqman Express plates run on a 7900
HT Taqman system (ABI). Total RNA was isolated from 1-
1.5610
6 NK cells using the GeneElute Mammalian Total RNA
isolation reagent (Sigma-Aldrich), samples were DNase treated
(Ambion) and 2 mg of RNA reverse transcribed using the high
capacity RNA-to-cDNA kit (from ABI). Resultant cDNA was
quantitated using TaqMan primers and probes from ABI as
follows (gene, assay ID); NCR1, Hs00183118_m1; KLRK1,
Hs00183683_m1; NCR3, Hs00394809_m1; CD226, Hs0017083
2_m1; GZMB, Hs00188051_m1; GZMH, Hs00277212_m1; PRF1,
Hs00169473_m1; HCST, Hs00367159_m1; CD247, Hs001679
01_m1. Gene expression was analysed using the comparative Ct
method (using 18S rRNA as the control) and are representative of
data from three separate donors, each with qRT-PCR reactions
performed in triplicate. Data are presented as fold change relative
to unstimulated NK cell samples (denoted as 1 arbitrary unit).
For protein expression, immunoblotting of granzyme B and
granzyme H (and the actin control) were performed using lysates
derived from 6610
4 or 1610
6 NK cells respectively as described
previously (50). For phosphorylated STAT5 and SMAD3, 1610
6
NK cells were lysed in 20 ml of RIPA buffer supplemented with
protease inhibitors (Set III without EDTA; Sigma Aldrich, Dorset,
UK) and 16PhosSTOP phosphatase inhibitors (Roche), cleared
by centrifugation at 16000 g for 5 mins before loading onto a 10%
SDS-PAGE gel. Proteins were subsequently transferred and
membranes blocked with 5% BSA, 0.1% Tween 20 in TBS for
1 hr at room temperature. Blots were probed with primary
antibody overnight at a dilution of 1:1000, in TBS containing
2.5% BSA, 0.1% Tween 20, washed 4 times in TBS, 0.1% Tween
20, followed by horseradish peroxidase conjugated anti-Rabbit
IgG antibody at 1:2000, left for 1 hr at room temperature and
washed as before. Antibodies used were phospho-SMAD3
(Ser423/425; clone C25A9) and reprobed for SMAD3 (C66
7H9); phospho-STAT5 (Tyr694) and reprobed for STAT5 (3H7)
all from Cell Signaling. Proteins were visualized using ECL
(GE Healthcare). STAT5 phosphorylation was analysed after
48 hrs of cytokine treatment whereas SMAD3 was analysed after
30 minutes.
For enzymatic assays, granzyme B activity was analysed as
aspartase activity by hydrolysis of the substrate AcIEPD-pNA
(Calbiochem) and cathepsin C activity by hydrolysis of GF-pNA
(Sigma Aldrich) as previously described [50].
Supporting Information
Figure S1 Inhibition of human NK cells following
chronic interaction with tumour cells. (A) Expression of
activation receptors (as indicated) by NK cells cultured in the
presence of IL-15, either with (green histogram) or without (red
histogram) the colorectal tumour cell line HCT116. Isotype
control stains are shown in grey and black. Co-culture was
performed for the time indicated and NK cells identified in the co-
culture as NKp46+ cells. (B) NK cell production of IFN-c
following chronic interaction with HCT116 cells for 48 hours. NK
cells were cultured with IL-15 in the presence or absence of
HCT116 cells as indicated. The NK cells were separated from the
tumour and restimulated with K562 cells or PMA/ionomycin (as
indicated). The percentage of cells producing IFN-c is indicated.
(C) NK cell granule exocytosis following chronic interaction with
HCT116 cells. This experiment was performed as in (B), except
that granule exocytosis was assayed by cell surface expression of
the granule membrane protein CD107a. In addition, NK cells
were separated from the tumour and cultured with IL-15 alone to
test recovery (as indicated). (D) Localised inhibition is reversible.
Expression of activation receptors (as indicated) by NK cells
cultured in 20 ng/ml of IL-15 in the presence (green histogram) or
absence (red histogram) of the colorectal tumour cell line
HCT116. NK cells were cultured in IL-15 alone or IL-15 plus
HCT116 cells for nine days, or for two days after which NK cells
were removed (by gentle washing) and cultured with IL-15 in the
absence of HCT116 for a further seven days (blue histogram). (E)
NK cell inhibition by HCT116 requires cell-cell contact.
Expression of activation receptors (as indicated) was determined
in 48 hr cultures of NK cell alone (in 20 ng/ml IL-15; red
histogram) or where the NK cells were separated from the
HCT116 in a transwell dish (green histogram). Black and grey are
isotype controls. (F) Inhibition by other tumour types. Expression
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20 ng/ml of IL-15 in the presence (green histogram) or absence
(red histogram) of the ovarian cancer cell lines SKOV3 or
OVCA433 (as indicated) for 48 hrs. NK cells were identified in the
co-culture by expression of NKp46. (G) NK cell production of
interferon (IFN)-c following chronic interaction with SKOV3 or
OVCA433 cells for 48 hours. NK cells were cultured in the
presence of 20 ng/ml IL-15 in the presence or absence of the
indicated tumour cell line. NK cells were removed from the
culture (by washing) and restimulated with the susceptible NK cell
target K562 for 5 hrs at an effector to target (E:T) ratio of 1:1 and
IFN-c production assayed by intracellular staining. NK cells were
identified by NKp46 expression. The percentage of cells
producing IFN-c is indicated. (H) Inhibition by tumour is greater
than immortalised cells. Expression of activation receptors (as
indicated) by NK cells cultured in 20 ng/ml of IL-15 alone (red
histogram) in the presence of Human Papillomavirus transformed
keratinocytes (the cervical carcinoma cell line HeLa; green
histogram) or with immortalised keratinocytes (HaCat; blue
histogram) for 48 hrs. (I) NK cell granule exocytosis following
chronic interaction with tumour cells (HeLa) or immortalised
keratinocytes (HaCat). This experiment was performed as in (D),
except that granule exocytosis was assayed by cell surface
expression of the granule membrane protein CD107a.
(TIF)
Figure S2 TGF-b dependent inhibition of NK cell killing
activity following chronic interactions. NK cells were
cultured for 48 hrs in 20 ng/ml IL-15 alone or in the presence
of the tumour cell line, HCT116. NK cells cultured with HCT116
included either an anti-TGF-b antibody or an isotype control
antibody. After 48 hrs, NK cells were sorted from all cultures. The
HCT116 cells express CD138 and NK cells were sorted based on
the absence of this marker. Sorted NK cells (.95% purity) were
used in a flow cytometric based killing assay of K562 cell line at an
E:T ratio of 2:1. The data shows the mean of three experiments
performed in triplicate, with standard deviation. Probability (P)
values are indicated (calculated using a Mann-Whitney test).
(TIF)
Figure S3 Localised NK cell inhibition by human
tumours in vivo. (A) Expression of activation receptors (as
indicated) on NK cells derived from the peripheral blood of
healthy donors (red histograms), the peripheral blood of five
ovarian cancer patients (P1–P5; blue histograms) and autologous
tumour-associated NK cells from the ascites fluid of P1–P5
(green histograms). NKG2D expression was not analysed in
sample P4. The grey and black histograms are isotype controls.
(B) Ascites-derived tumour cells express epithelial markers
associated with ovarian cancer. Ascites were plated and cells
left to adhere (for 24–48 hrs). Non-adherent cells were used as a
source of NK cells and the adherent cells were analysed for cell
surface expression of HER2, MUC1 and MUC16 associated
with the ovarian cancer phenotype [11] and the NK cell markers
NKp46 and CD56. In addition, adherent cells were tested for
intracellular expression of TGF-b. The adherent cell samples
contained no more than 10% fibroblasts. (C) Relative propor-
tions of CD56
bright and CD56
dim NK cells in the NK cell
populations derived from patient blood and patient ascites
(patients 1–4) as well as from healthy controls. NK cells were
identified as CD56+CD3
neg and the percentage of CD56
bright
NK cells are indicated on each plot. The results show that the
tumour associated NK cells have a higher proportion of
CD56
bright NK cells compared to the matched peripheral blood
(and to blood from healthy controls), as previously shown (11).
For Patient 5, NK cells were identified via NKp46 expression
and CD56
bright and CD56
dim data was not analysed. For patients
1–4, we analysed the expression of DNAM-1 on the CD56
bright
and CD56
dim NK cells in the matched ascites and blood samples.
The figures in brackets correspond to the ratio of DNAM-1
expression (as assessed by the geometric mean of fluorescence) in
ascites/peripheral blood NK cells for CD56
bright and CD56
dim
cells. Thus for patient 1, the values (0.14, 0.12) indicate that
DNAM-1 expression in ascites derived CD56
bright NK cells was
0.14 times that observed in peripheral blood and for CD56
dim
NK cells, DNAM-1 was expressed at 0.12 times that in
peripheral blood. This data indicates that DNAM-1 expression
was downregulated at similar levels on both subsets of tumour-
associated NK cells.
(TIF)
Figure S4 Antagonism of TGF-b mediated inhibition
following chronic interactions. (A) Effect of the TGF-b
signalling inhibitor SB-431542 on inhibition mediated by
HCT116. NK cells were cultured in 20 ng/ml IL-15 alone or
with HCT116, in the presence of either SB-431542 or DMSO (as
indicated). NK cells were removed from the culture (by gentle
washing) and restimulated with the NK cell target K562 for 5 hrs
at an effector to target (E:T) ratio of 1:1 and IFN-c production
assayed by intracellular staining. NK cells were identified by
NKp46 expression. The percentage of cells producing IFN-c is
indicated. (B) NK cell granule exocytosis following chronic
interaction with HCT116 cells in the presence of SB-431542 or
DMSO. This experiment was performed as in (A), except that
granule exocytosis was assayed by cell surface expression of the
granule membrane protein CD107a.
(TIF)
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